Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.57
AZN's Cash to Debt is ranked higher than
60% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. AZN: 0.57 )
AZN' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: 0.57

Equity to Asset 0.38
AZN's Equity to Asset is ranked higher than
52% of the 754 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. AZN: 0.38 )
AZN' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.59
Current: 0.38

0.3
0.59
Interest Coverage 7.50
AZN's Interest Coverage is ranked higher than
54% of the 488 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.25 vs. AZN: 7.50 )
AZN' s 10-Year Interest Coverage Range
Min: 6.94   Max: 100.5
Current: 7.5

6.94
100.5
F-Score: 4
Z-Score: 2.58
M-Score: -3.36
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 11.82
AZN's Operating margin (%) is ranked higher than
79% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.92 vs. AZN: 11.82 )
AZN' s 10-Year Operating margin (%) Range
Min: 12.32   Max: 38.09
Current: 11.82

12.32
38.09
Net-margin (%) 7.82
AZN's Net-margin (%) is ranked higher than
78% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.26 vs. AZN: 7.82 )
AZN' s 10-Year Net-margin (%) Range
Min: 6.86   Max: 29.72
Current: 7.82

6.86
29.72
ROE (%) 8.79
AZN's ROE (%) is ranked higher than
78% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.33 vs. AZN: 8.79 )
AZN' s 10-Year ROE (%) Range
Min: 10.72   Max: 45.6
Current: 8.79

10.72
45.6
ROA (%) 3.54
AZN's ROA (%) is ranked higher than
73% of the 814 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.07 vs. AZN: 3.54 )
AZN' s 10-Year ROA (%) Range
Min: 4.6   Max: 21.04
Current: 3.54

4.6
21.04
ROC (Joel Greenblatt) (%) 51.06
AZN's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.20 vs. AZN: 51.06 )
AZN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 33.33   Max: 192.75
Current: 51.06

33.33
192.75
Revenue Growth (%) -5.10
AZN's Revenue Growth (%) is ranked higher than
55% of the 655 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. AZN: -5.10 )
AZN' s 10-Year Revenue Growth (%) Range
Min: -54.5   Max: 87.7
Current: -5.1

-54.5
87.7
EBITDA Growth (%) -14.50
AZN's EBITDA Growth (%) is ranked higher than
56% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. AZN: -14.50 )
AZN' s 10-Year EBITDA Growth (%) Range
Min: -40.8   Max: 112.8
Current: -14.5

-40.8
112.8
EPS Growth (%) -29.50
AZN's EPS Growth (%) is ranked higher than
57% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. AZN: -29.50 )
AZN' s 10-Year EPS Growth (%) Range
Min: -29.5   Max: 71.5
Current: -29.5

-29.5
71.5
» AZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AZN Guru Trades in Q3 2013

Steven Cohen 532,113 sh (+4346.87%)
Pioneer Investments 590,122 sh (+23.7%)
Charles Brandes 2,381,040 sh (+7.92%)
David Dreman 179,261 sh (+4.4%)
Murray Stahl 12,020 sh (+0.17%)
NWQ Managers 85,850 sh (unchged)
Manning & Napier Advisors, Inc 508,945 sh (-0.53%)
HOTCHKIS & WILEY 4,912,449 sh (-0.65%)
Jim Simons 2,913,800 sh (-14.94%)
John Hussman 68,000 sh (-81.87%)
» More
Q4 2013

AZN Guru Trades in Q4 2013

Francis Chou 13,000 sh (New)
Stanley Druckenmiller 360,500 sh (New)
Pioneer Investments 651,839 sh (+10.46%)
Charles Brandes 2,503,848 sh (+5.16%)
Steven Cohen 533,262 sh (+0.22%)
Murray Stahl 12,020 sh (unchged)
NWQ Managers 85,450 sh (-0.47%)
Manning & Napier Advisors, Inc 490,878 sh (-3.55%)
Jim Simons 2,715,400 sh (-6.81%)
HOTCHKIS & WILEY 3,689,214 sh (-24.9%)
David Dreman 106,975 sh (-40.32%)
John Hussman 28,000 sh (-58.82%)
» More
Q1 2014

AZN Guru Trades in Q1 2014

Joel Greenblatt 95,518 sh (New)
John Hussman 228,000 sh (+714.29%)
David Dreman 135,439 sh (+26.61%)
Murray Stahl 13,106 sh (+9.03%)
NWQ Managers 85,450 sh (unchged)
Stanley Druckenmiller 360,500 sh (unchged)
Francis Chou 13,000 sh (unchged)
HOTCHKIS & WILEY Sold Out
Manning & Napier Advisors, Inc 459,569 sh (-6.38%)
Pioneer Investments 459,298 sh (-29.54%)
Steven Cohen 367,034 sh (-31.17%)
Charles Brandes 1,333,894 sh (-46.73%)
Jim Simons 1,429,000 sh (-47.37%)
» More
Q2 2014

AZN Guru Trades in Q2 2014

Paul Tudor Jones 27,100 sh (New)
Louis Moore Bacon 40,000 sh (New)
Mario Gabelli 40,400 sh (New)
Jeremy Grantham 28,000 sh (New)
George Soros 150,000 sh (New)
Jim Simons 1,794,800 sh (+25.6%)
Steven Cohen 370,800 sh (unchged)
Daniel Loeb 1,000,000 sh (unchged)
Steven Cohen 225,000 sh (unchged)
Francis Chou 13,000 sh (unchged)
Joel Greenblatt Sold Out
Murray Stahl 13,000 sh (-0.81%)
John Hussman 223,500 sh (-1.97%)
David Dreman 117,832 sh (-13%)
NWQ Managers 64,475 sh (-24.55%)
Manning & Napier Advisors, Inc 309,030 sh (-32.76%)
Stanley Druckenmiller 208,900 sh (-42.05%)
Pioneer Investments 225,804 sh (-50.84%)
Charles Brandes 386,058 sh (-71.06%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2014-06-30 Reduce -71.06%0.78%$62.45 - $81.09 $ 70.62-2%386058
Joel Greenblatt 2014-06-30 Sold Out 0.09%$62.45 - $81.09 $ 70.62-2%0
George Soros 2014-06-30 New Buy0.08%$62.45 - $81.09 $ 70.62-2%150000
Mario Gabelli 2014-06-30 New Buy0.02%$62.45 - $81.09 $ 70.62-2%40400
John Hussman 2014-03-31 Add 714.29%0.96%$58.51 - $68.15 $ 70.6210%228000
Charles Brandes 2014-03-31 Reduce -46.73%0.84%$58.51 - $68.15 $ 70.6210%1333894
David Dreman 2014-03-31 Add 26.61%0.14%$58.51 - $68.38 $ 70.6210%135439
Joel Greenblatt 2014-03-31 New Buy0.09%$58.51 - $68.38 $ 70.6210%95518
David Dreman 2013-12-31 Reduce -40.32%0.34%$49.72 - $59.5 $ 70.6230%106975
John Hussman 2013-12-31 Reduce -58.82%0.11%$49.72 - $59.5 $ 70.6230%28000
John Hussman 2013-09-30 Reduce -81.87%0.66%$47.88 - $52.08 $ 70.6241%68000
Charles Brandes 2013-09-30 Add 7.92%0.12%$47.88 - $52.08 $ 70.6241%2381040
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 45.80
AZN's P/E(ttm) is ranked higher than
74% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.30 vs. AZN: 45.80 )
AZN' s 10-Year P/E(ttm) Range
Min: 6.07   Max: 47.24
Current: 45.8

6.07
47.24
P/B 4.34
AZN's P/B is ranked higher than
66% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.39 vs. AZN: 4.34 )
AZN' s 10-Year P/B Range
Min: 2.31   Max: 7.02
Current: 4.34

2.31
7.02
P/S 3.57
AZN's P/S is ranked higher than
73% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.81 vs. AZN: 3.57 )
AZN' s 10-Year P/S Range
Min: 1.6   Max: 4.13
Current: 3.57

1.6
4.13
PFCF 12.48
AZN's PFCF is ranked higher than
97% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. AZN: 12.48 )
AZN' s 10-Year PFCF Range
Min: 6.22   Max: 38.17
Current: 12.48

6.22
38.17
EV-to-EBIT 31.72
AZN's EV-to-EBIT is ranked higher than
75% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.17 vs. AZN: 31.72 )
AZN' s 10-Year EV-to-EBIT Range
Min: 4.5   Max: 32.7
Current: 31.72

4.5
32.7
Shiller P/E 14.05
AZN's Shiller P/E is ranked higher than
96% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.28 vs. AZN: 14.05 )
AZN' s 10-Year Shiller P/E Range
Min: 8.1   Max: 27.94
Current: 14.05

8.1
27.94
Current Ratio 0.99
AZN's Current Ratio is ranked lower than
51% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. AZN: 0.99 )
AZN' s 10-Year Current Ratio Range
Min: 0.64   Max: 2.03
Current: 0.99

0.64
2.03
Quick Ratio 0.85
AZN's Quick Ratio is ranked higher than
52% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. AZN: 0.85 )
AZN' s 10-Year Quick Ratio Range
Min: 0.54   Max: 2.03
Current: 0.85

0.54
2.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.00
AZN's Dividend Yield is ranked higher than
95% of the 489 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. AZN: 4.00 )
AZN' s 10-Year Dividend Yield Range
Min: 1.68   Max: 6.75
Current: 4

1.68
6.75
Dividend Payout 1.74
AZN's Dividend Payout is ranked higher than
82% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. AZN: 1.74 )
AZN' s 10-Year Dividend Payout Range
Min: 0.24   Max: 4.87
Current: 1.74

0.24
4.87
Dividend growth (3y) 3.20
AZN's Dividend growth (3y) is ranked higher than
81% of the 359 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. AZN: 3.20 )
AZN' s 10-Year Dividend growth (3y) Range
Min: -6.3   Max: 30.1
Current: 3.2

-6.3
30.1
Yield on cost (5-Year) 5.66
AZN's Yield on cost (5-Year) is ranked higher than
95% of the 496 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. AZN: 5.66 )
AZN' s 10-Year Yield on cost (5-Year) Range
Min: 2.38   Max: 9.56
Current: 5.66

2.38
9.56
Share Buyback Rate 4.60
AZN's Share Buyback Rate is ranked higher than
92% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.20 vs. AZN: 4.60 )
AZN' s 10-Year Share Buyback Rate Range
Min: 43.7   Max: -144.8
Current: 4.6

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.07
AZN's Price/DCF (Projected) is ranked higher than
94% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.11 vs. AZN: 1.07 )
AZN' s 10-Year Price/DCF (Projected) Range
Min: 0.49   Max: 4.43
Current: 1.07

0.49
4.43
Price/Median PS Value 1.50
AZN's Price/Median PS Value is ranked higher than
64% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.27 vs. AZN: 1.50 )
AZN' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 2.48
Current: 1.5

0.7
2.48
Earnings Yield (Greenblatt) 3.20
AZN's Earnings Yield (Greenblatt) is ranked higher than
65% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. AZN: 3.20 )
AZN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 22.2
Current: 3.2

3.1
22.2
Forward Rate of Return (Yacktman) 0.40
AZN's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. AZN: 0.40 )
AZN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.3   Max: 30.2
Current: 0.4

-1.3
30.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:AZN.Sweden, AZNDF.USA, AZN.UK, ZEGA.Germany, ZEG.Germany, AZNCF.USA, AZN N.Mexico
AstraZeneca PLC is engaged in the global, prescription-based biopharmaceutical business. Its pharmaceuticals business consists of the discovery and development of new products, which are then manufactured, marketed and sold. It focuses on six therapy areas of healthcare such as Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory & Inflammation. The Company has operations in the United Kingdom, Continental Europe, The Americas, Asia, Africa, and Australia.
» More Articles for NYSE:AZN

Headlines

Articles On GuruFocus.com
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
Can Pfizer Make Up Its Loss? May 09 2014 
Abbott Capturing Incremental Market Share Mar 18 2014 
Abbvie's Humira Continues to be a Powerful Catalyst for Growth Mar 18 2014 
10 British Stocks to Consider Feb 20 2014 
Bristol-Myers: Don’t Let This One Get Away Jan 15 2014 
AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 


More From Other Websites
Esperion drug succeeds in lowering LDL cholesterol -study Oct 01 2014
Esperion drug succeeds in lowering LDL cholesterol -study Oct 01 2014
Bristol-Myers' Opdivo under Review in EU for Lung Cancer Oct 01 2014
Ardelyx Bowel Drug Could Rival Actavis' Linzess Oct 01 2014
I'm Shocked, Shocked To Find That Pharma Is Paying Doctors! Oct 01 2014
Why You Should Let AstraZeneca plc Look After Your Money Oct 01 2014
Nektar/AstraZeneca's Moventig a Step Closer to EU Approval Sep 29 2014
Clovis Shares Higher on Improved Outlook for Lung Cancer Drug Sep 29 2014
Cancer drug stocks on the move amid striking data Sep 29 2014
7:50 am AstraZeneca updates on progress of oncology pipeline at ESMO 2014 congress Sep 29 2014
GlaxoSmithKline plc Is Still A Better Pick Than AstraZeneca plc Sep 29 2014
Bristol immune drug shows strong effect in melanoma study Sep 29 2014
Bristol immune drug shows strong effect in melanoma study Sep 29 2014
Merck drug extends immune system fight to stomach cancer Sep 28 2014
No benefit from continued use of AstraZeneca's Iressa drug Sep 28 2014
Bristol immunotherapy gets 6-month U.S. FDA review for melanoma Sep 26 2014
EU agency backs AstraZeneca's MOVENTIG drug Sep 26 2014
AstraZeneca says expanded use of lung cancer drug backed by EU agency Sep 26 2014
AstraZeneca says expanded use of lung cancer drug backed by EU agency Sep 26 2014
Why IGI Laboratories (IG) Stock Hit a One-Year High Today Sep 25 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK